BUSINESS WIRE
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today announced that preclinical data supporting
the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875,
will be presented in a poster session at the Association for Research in
Vision and Ophthalmology, Inc. (ARVO) 2009 Annual Meeting in Fort
Lauderdale, FL. INO-8875 is a highly selective adenosine-1 receptor
agonist currently completing a Phase 1/2 trial as a topical agent for
the treatment of elevated intraocular pressure (IOP) associated with
primary open angle glaucoma and ocular hypertension. The preclinical
data suggests that INO-8875 lowers IOP primarily by restoring trabecular
meshwork outflow, the most important outflow pathway to maintain IOP in
healthy eyes. Additionally, INO-8875 may have a secondary mechanism of
action to decrease IOP by reducing aqueous humor production.
Norman Kim, M.S., DABT, Senior Director, Preclinical Development at
Inotek will present the results of Abstract #4061/A223 entitled
“INO-8875, An Adenosine A1 Agonist, in Development for Open-Angle
Glaucoma Reduces IOP in Three Rabbit Models” on Wednesday, May 06, 2009
at 8:30 AM ET.
About Inotek Pharmaceuticals
Inotek is a clinical-stage pharmaceutical company developing ophthalmic
therapies with novel mechanisms of action to address significant
diseases of the eye. The Company has an emerging pipeline of drug
candidates targeting a broad range of ophthalmic diseases, including
glaucoma, age-related macular degeneration, and diabetic retinopathy.